Hoe verhoudt UBI's PS Ratio zich tot zijn concurrenten?

UBI is good value based on its Price-To-Sales Ratio (5.3x) compared to the peer average (5.7x).

Hoe verhoudt UBI's PS Ratio zich tot andere bedrijven in de AU Medical Equipment industrie?

UBI is expensive based on its Price-To-Sales Ratio (5.3x) compared to the Australian Medical Equipment industry average (3.3x).

Wat is UBI's PS Ratio vergeleken met zijn Fair PS Ratio? Dit is de verwachte PS Ratio, rekening houdend met de verwachte winstgroei van het bedrijf, winstmarges en andere risicofactoren.

Insufficient data to calculate UBI's Price-To-Sales Fair Ratio for valuation analysis.

Wat is de reële prijs van UBI als we kijken naar de toekomstige kasstromen? Voor deze schatting gebruiken we een Discounted Cash Flow-model.

Insufficient data to calculate UBI's fair value for valuation analysis.

Wat is de 12-maandsprognose van de analisten en hebben we enig statistisch vertrouwen in het consensuskoersdoel?

Insufficient data to show price forecast.

Universal Biosensors (ASX:UBI) - Aandelenkoers, Nieuws & Analyse

UBI Overzicht aandelen

Universal Biosensors, Inc. ontwerpt en ontwikkelt via haar dochterondernemingen elektrochemische cellen (strips) die worden gebruikt in combinatie met apparaten voor gebruik op de plaats van bestemming in de gezondheidszorg (point-of-care), de wijn-, voedsel- en landbouwindustrie in Australië, Noord- en Zuid-Amerika, Europa en internationaal.

Over het bedrijf

UBI fundamentele analyse
Sneeuwvlok Score
Waardering	1/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	4/6
Dividenden	0/6

Beloningen

Risicoanalyse

Has less than 1 year of cash runway

Earnings have declined by 18.7% per year over past 5 years

Shareholders have been diluted in the past year

Does not have a meaningful market cap (A$37M)

+ 1 meer risico

Universal Biosensors, Inc. Concurrenten

Nova Eye Medical

ASX:EYE

AU$37.8m

LBT Innovations

ASX:LBT

AU$24.5m

Compumedics

ASX:CMP

AU$56.0m

SomnoMed

ASX:SOM

AU$67.0m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Universal Biosensors
Historische aandelenkoersen
Huidige aandelenkoers	AU$0.13
52 Week Hoogtepunt	AU$0.30
52 Week Laag	AU$0.12
Bèta	0.93
11 maand verandering	-13.79%
3 maanden verandering	4.17%
1 Jaar Verandering	-50.00%
33 jaar verandering	-83.87%
5 jaar verandering	-32.43%
Verandering sinds IPO	-87.50%

Recent nieuws en updates

Recent updates

We Think Universal Biosensors (ASX:UBI) Needs To Drive Business Growth Carefully

Nov 09

We're Keeping An Eye On Universal Biosensors' (ASX:UBI) Cash Burn Rate

May 03

We Think Universal Biosensors (ASX:UBI) Needs To Drive Business Growth Carefully

Jan 12

We're Keeping An Eye On Universal Biosensors' (ASX:UBI) Cash Burn Rate

Oct 10

Companies Like Universal Biosensors (ASX:UBI) Are In A Position To Invest In Growth

Apr 28

We Think Universal Biosensors (ASX:UBI) Can Afford To Drive Business Growth

May 13

Should You Take Comfort From Insider Transactions At Universal Biosensors, Inc. (ASX:UBI)?

Feb 24

We Think Universal Biosensors (ASX:UBI) Can Afford To Drive Business Growth

Jan 20

The Universal Biosensors (ASX:UBI) Share Price Has Gained 95% And Shareholders Are Hoping For More

Dec 15

Rendement voor aandeelhouders

	UBI	AU Medical Equipment	AU Markt
7D	-7.4%	-0.6%	-1.1%
1Y	-50.0%	15.2%	16.1%

Rendement versus industrie: UBI underperformed the Australian Medical Equipment industry which returned 15.2% over the past year.

Rendement versus markt: UBI underperformed the Australian Market which returned 16.1% over the past year.

Prijsvolatiliteit

Is UBI's price volatile compared to industry and market?
UBI volatility
UBI Average Weekly Movement	10.7%
Medical Equipment Industry Average Movement	10.1%
Market Average Movement	8.6%
10% most volatile stocks in AU Market	17.5%
10% least volatile stocks in AU Market	3.6%

Stabiele aandelenkoers: UBI has not had significant price volatility in the past 3 months compared to the Australian market.

Volatiliteit in de loop van de tijd: UBI's weekly volatility (11%) has been stable over the past year.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2001	80	John Sharman	www.universalbiosensors.com

Universal Biosensors, Inc. ontwerpt en ontwikkelt via haar dochterondernemingen elektrochemische cellen (strips) die gebruikt worden in combinatie met apparaten voor gebruik op de plaats van bestemming in de gezondheidszorg (point-of-care), de wijn-, voedsel- en landbouwindustrie in Australië, Noord- en Zuid-Amerika, Europa en internationaal. Het bedrijf produceert en distribueert Protrombin Time International Normalized Ratio stollingsteststrips en Xprecia Stride en Xprecia Prime medische apparaten om het effect van de antistollingstherapie warfarine te controleren; en Sentia wijntestproducten, zoals vrije SO2, appelzuur, glucose, fructose, totaal zuur en titreerbare zuurgraad. Het bedrijf biedt ook niet-diagnostische laboratoriumdiensten en voert stollingstests uit.

Universal Biosensors, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Universal Biosensors zich tot de beurswaarde?
UBI fundamentele statistieken
Marktkapitalisatie	AU$37.26m
Inkomsten(TTM)	-AU$12.39m
Inkomsten(TTM)	AU$7.08m

5.3x

P/S-verhouding

-3.0x

Koers/Winstverhouding

Is UBI overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
UBI resultatenrekening (TTM)
Inkomsten	AU$7.08m
Kosten van inkomsten	AU$3.05m
Brutowinst	AU$4.03m
Overige uitgaven	AU$16.43m
Inkomsten	-AU$12.39m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.042
Brutomarge	56.95%
Nettowinstmarge	-175.04%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde UBI op de lange termijn?

Bekijk historische prestaties en vergelijking

UBI Overzicht aandelen

Beloningen

Risicoanalyse

Universal Biosensors, Inc. Concurrenten

ASX:EYE

AU$37.8m

ASX:LBT

AU$24.5m

ASX:CMP

AU$56.0m

ASX:SOM

AU$67.0m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

New major risk - Financial position

Third quarter 2024 earnings released: AU$0.011 loss per share (vs AU$0.012 loss in 3Q 2023)

Universal Biosensors, Inc. to Report First Half, 2024 Results on Aug 09, 2024

Second quarter 2024 earnings released: AU$0.014 loss per share (vs AU$0.007 profit in 2Q 2023)

Non-Executive Director recently bought AU$50k worth of stock

First quarter 2024 earnings released: AU$0.016 loss per share (vs AU$0.018 loss in 1Q 2023)

Recent updates

New major risk - Financial position

Third quarter 2024 earnings released: AU$0.011 loss per share (vs AU$0.012 loss in 3Q 2023)

Universal Biosensors, Inc. to Report First Half, 2024 Results on Aug 09, 2024

Second quarter 2024 earnings released: AU$0.014 loss per share (vs AU$0.007 profit in 2Q 2023)

Non-Executive Director recently bought AU$50k worth of stock

First quarter 2024 earnings released: AU$0.016 loss per share (vs AU$0.018 loss in 1Q 2023)

Universal Biosensors, Inc., Annual General Meeting, May 30, 2024

New minor risk - Shareholder dilution

Universal Biosensors, Inc., Annual General Meeting, Apr 10, 2024

New minor risk - Shareholder dilution

Chief Executive Officer exercised options to buy AU$259k worth of stock.

Universal Biosensors, Inc. has completed a Follow-on Equity Offering in the amount of AUD 2.5 million.

Universal Biosensors, Inc. to Report Fiscal Year 2023 Results on Mar 07, 2024

Universal Biosensors, Inc. has filed a Follow-on Equity Offering in the amount of AUD 10 million.

We Think Universal Biosensors (ASX:UBI) Needs To Drive Business Growth Carefully

Third quarter 2023 earnings released: AU$0.012 loss per share (vs AU$0.024 loss in 3Q 2022)

New minor risk - Financial position

Second quarter 2023 earnings released: EPS: AU$0.007 (vs AU$0.024 loss in 2Q 2022)

New minor risk - Share price stability

First quarter 2023 earnings released: AU$0.018 loss per share (vs AU$0.025 loss in 1Q 2022)

We're Keeping An Eye On Universal Biosensors' (ASX:UBI) Cash Burn Rate

Full year 2022 earnings: EPS and revenues miss analyst expectations

Universal Biosensors, Inc. Launches New Product, Fructose Test for Sentia

Universal Biosensors, Inc. completes Xprecia Prime clinical trial in USA

Universal Biosensors, Inc. Announces Chairman Changes

We Think Universal Biosensors (ASX:UBI) Needs To Drive Business Growth Carefully

Non-Executive Chairman recently bought AU$54k worth of stock

Price target increased to AU$1.15

Third quarter 2022 earnings released: AU$0.024 loss per share (vs AU$0.016 loss in 3Q 2021)

Price target increased to AU$1.15

We're Keeping An Eye On Universal Biosensors' (ASX:UBI) Cash Burn Rate

Non-Executive Chairman recently bought AU$56k worth of stock

Consensus revenue estimates fall by 19%

Second quarter 2022 earnings released: AU$0.024 loss per share (vs AU$0.01 loss in 2Q 2021)

Consensus revenue estimates fall by 10%

Universal Biosensors, Inc. has completed a Follow-on Equity Offering in the amount of AUD 20.007467 million.

First quarter 2022 earnings released: AU$0.025 loss per share (vs AU$0.008 loss in 1Q 2021)

Universal Biosensors, Inc., Annual General Meeting, Jun 21, 2022

Companies Like Universal Biosensors (ASX:UBI) Are In A Position To Invest In Growth

Price target increased to AU$1.25

Forecast to breakeven in 2024

Universal Biosensors, Inc. Announces Interim Results from the Peter Mac Sponsored Tn Antigen Development Clinical Study

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Universal Biosensors, Inc. Announces the Launch of the Sentia Malic Acid Test into the Global Wine Market

Second quarter 2021 earnings released: AU$0.01 loss per share (vs AU$0.017 loss in 2Q 2020)

We Think Universal Biosensors (ASX:UBI) Can Afford To Drive Business Growth

First quarter 2021 earnings released: AU$0.008 loss per share (vs AU$0.008 loss in 1Q 2020)

Independent Non-Executive Director has left the company

Universal Biosensors, Inc. Announces Resignation of Marshall Heinberg as Director

Full year 2020 earnings released: AU$0.043 loss per share (vs AU$0.027 loss in FY 2019)

Should You Take Comfort From Insider Transactions At Universal Biosensors, Inc. (ASX:UBI)?

Universal Biosensors, Inc. Enters into Non-Exclusive Distribution Agreement with Enartis Inc

We Think Universal Biosensors (ASX:UBI) Can Afford To Drive Business Growth

New 90-day high: AU$0.54

The Universal Biosensors (ASX:UBI) Share Price Has Gained 95% And Shareholders Are Hoping For More

Universal Biosensors, Inc. Releases SENTIA

New 90-day high: AU$0.34

Independent Non-Executive Director recently bought AU$62k worth of stock

Universal Biosensors, Inc. Announces Appointment of Promedeus s.r.o. as Its New Distribution Partner in Czech Republic and Slovak Republic